Literature DB >> 22488644

Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Stephen J Cleland1.   

Abstract

Historically, clinical management of patients with type 1 diabetes mellitus (T1DM) has been focused on glycaemic control, which is sometimes achieved at the expense of weight gain on intensive insulin regimes. Although HbA(1c) level is an important contributor to increased macrovascular risk, several prospective studies have concluded that factors related to obesity, metabolic syndrome and insulin resistance are more important than HbA(1c) for the prediction of cardiovascular risk, especially for coronary heart disease events. 'Double diabetes mellitus' describes a combination of T1DM with characteristics associated with type 2 diabetes mellitus, including central adiposity and exacerbation of insulin resistance. In lean patients with T1DM, portal insulinopaenia might actually confer cardioprotective effects via changes in hepatic lipid profiles (mainly increased HDL cholesterol levels) and a reduction in hepatic steatosis. In patients with double diabetes mellitus, this situation is reversed and atherothrombotic pathophysiology is potentially accelerated by the combination of chronic hyperglycaemia and abnormal lipid partitioning. The prevalence of double diabetes mellitus is increasing in parallel with the societal trend of increased adiposity. This Review discusses how to identify patients susceptible to double diabetes mellitus and suggests alterations to their clinical management that might reduce their risk of future premature coronary disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488644     DOI: 10.1038/nrendo.2012.47

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  86 in total

Review 1.  The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD.

Authors:  Michaela Diamant; Maarten E Tushuizen
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

2.  All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999.

Authors:  S S Soedamah-Muthu; J H Fuller; H E Mulnier; V S Raleigh; R A Lawrenson; H M Colhoun
Journal:  Diabetologia       Date:  2006-01-24       Impact factor: 10.122

3.  Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial.

Authors:  Eric S Kilpatrick; Alan S Rigby; Stephen L Atkin
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

4.  The effect of rosiglitazone on overweight subjects with type 1 diabetes.

Authors:  Suzanne M Strowig; Philip Raskin
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

5.  Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes.

Authors:  Jon C Olson; John R Erbey; Kimberly Y Z Forrest; Katherine Williams; Dorothy J Becker; Trevor J Orchard
Journal:  Metabolism       Date:  2002-02       Impact factor: 8.694

6.  Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients.

Authors:  H Gin; C Messerchmitt; E Brottier; J Aubertin
Journal:  Metabolism       Date:  1985-10       Impact factor: 8.694

Review 7.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

Review 8.  Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone.

Authors:  A D Baron
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-10

Review 9.  Addressing insulin resistance in Type 1 diabetes.

Authors:  T T L Pang; P Narendran
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

10.  Insulin receptor function and glycogen synthase activity in skeletal muscle biopsies from patients with insulin-dependent diabetes mellitus: effects of physical training.

Authors:  J F Bak; U K Jacobsen; F S Jørgensen; O Pedersen
Journal:  J Clin Endocrinol Metab       Date:  1989-07       Impact factor: 5.958

View more
  22 in total

1.  Circulating MiRNA biomarkers serve as a fingerprint for diabetic atherosclerosis.

Authors:  Jing-Yun Zhang; Ying-Lan Gong; Chun-Jun Li; Qi Qi; Qiu-Mei Zhang; De-Min Yu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Renal and extrarenal actions of Klotho.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

Review 3.  The two faces of miR-29.

Authors:  Anna Ślusarz; Lakshmi Pulakat
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2015-07       Impact factor: 2.160

4.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.

Authors:  Haifeng Ye; Ghislaine Charpin-El Hamri; Katharina Zwicky; Matthias Christen; Marc Folcher; Martin Fussenegger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Impact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice.

Authors:  Piotr Zabielski; Agnieszka Blachnio-Zabielska; Ian R Lanza; Srinivas Gopala; S Manjunatha; Daniel R Jakaitis; Xuan-Mai Persson; Jaime Gransee; Katherine A Klaus; Jill M Schimke; Michael D Jensen; K Sreekumaran Nair
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-24       Impact factor: 4.310

Review 6.  Lipids and the endothelium: bidirectional interactions.

Authors:  Ira J Goldberg; Karin E Bornfeldt
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

7.  Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey.

Authors:  Fernando M A Giuffrida; Alexis D Guedes; Eloa R Rocco; Denise B Mory; Patricia Dualib; Odelisa S Matos; Reine M Chaves-Fonseca; Roberta A Cobas; Carlos Antonio Negrato; Marilia B Gomes; Sergio A Dib
Journal:  Cardiovasc Diabetol       Date:  2012-12-27       Impact factor: 9.951

8.  Regulation of cardiac expression of the diabetic marker microRNA miR-29.

Authors:  Nicholas Arnold; Purushotham Reddy Koppula; Rukhsana Gul; Christian Luck; Lakshmi Pulakat
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

9.  Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus.

Authors:  Aldo Ferreira-Hermosillo; Claudia Ramírez-Rentería; Victoria Mendoza-Zubieta; Mario A Molina-Ayala
Journal:  Diabetol Metab Syndr       Date:  2014-03-04       Impact factor: 3.320

10.  Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and HbA1c and is associated with improved glycemic control in clinical practice.

Authors:  Stephen A Varvel; Szilard Voros; Dawn L Thiselton; James V Pottala; Tara Dall; G Russell Warnick; Joseph P McConnell; Leila Ghaedi; Maciek Sasinowski; Timothy Graham
Journal:  J Cardiovasc Transl Res       Date:  2014-07-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.